Rob Kindler, an M&A partner at Paul Weiss, discusses his career as an M&A lawyer and banker, doing deals at Morgan Stanley and the importance of lifelong connectivity.

When corporations install anti-activist poison pills they're less likely to implement new share buybacks and their operationally focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.

Joele Frank discusses how she came to public relations and her approach to growing her own firm.

Solomon Partners head of business services Tim Shea discusses private equity's growing interest in residential and facilities services and dealmaking activity in the market in 2025.

Bruce Goldfarb, CEO and president of Okapi Partners, discusses launching the proxy solicitor in 2008 and how the client service skills he learned working in his father's dry cleaning business are relevant on Wall Street.

As the markets face tariff-related volatility, some companies, especially biotechnology and pharmaceuticals companies, are setting up or extending shareholder rights plans, known as poison pills, to discourage unsolicited bidders and activist accumulations.

While drone technology advanced during the Ukraine war, companies such as AeroVironment and Redwire have diversified portfolios through M&A.

Kimberly Petillo-Décossard, the co-head of M&A at White & Case, discusses building her career, her decision to change firms and how her husband's willingness to retire from his career as a banker has been pivotal to her success.